Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine.
Menopause. 2022 May 1;29(5):553-563. doi: 10.1097/GME.0000000000001949.
To understand prevalence, severity, impact, and treatment of vasomotor symptoms associated with menopause, using cross-sectional survey data.
This online, two-part survey was conducted in East Asia among women 40-65 years recruited from established online panels (Edelman, Beijing; Hankook Research, Seoul; Rakuten Insight, Taipei) using stratified sampling. Part I collected demographics/disease characteristics, including menopausal status and vasomotor symptom severity. Women with moderate-to-severe vasomotor symptoms completed Part II, including clinical characteristics, health-related quality of life, and healthcare-seeking behavior. Primary endpoints included vasomotor symptom prevalence and severity and proportions of women eligible and willing to take hormone therapy. Results are presented for each of the three online panels separately and as a pooled total. All analyses are descriptive with no formal hypothesis testing across groups.
Numbers of peri- versus postmenopausal women completing Part I were Edelman, 1,588 (55.1% vs 44.9%); Hankook Research, 1,000 (43.6% vs 56.4%); Rakuten Insight, 773 (61.7% vs 38.3%). Vasomotor symptom prevalence was =80% in each region; overall moderate-to-severe vasomotor symptom prevalence was 55%; >50% of women were untreated. Most of those treated used non-prescription treatments. Menopausal hormone therapy use was reported by 11.6% of peri- and 7.2% of postmenopausal women. In peri- and postmenopausal women with moderate-to-severe vasomotor symptoms, 8.6% and 3.4%, respectively, were hormone therapy-willing, 19.3% and 16.8% hormone therapy-contraindicated, 25.4% and 23.0% hormone therapy-cautious, and 10.2% and 8.3% hormone therapy-averse. Women experienced significant burden on health-related quality of life and substantial impairment of work productivity and daily activities.
Vasomotor symptoms associated with menopause affected =80% of women aged 40 to 65 years. A substantial proportion of women are unsuitable for, or choose not to take, menopausal hormone therapy, resulting in an unmet need for nonhormonal treatment options.
通过横断面调查数据了解与绝经相关的血管舒缩症状的流行率、严重程度、影响和治疗情况。
这项在线的两部分调查在东亚进行，参与者为来自已建立的在线小组（艾德曼，北京；韩康研究所，首尔；乐天洞察，台北）的 40-65 岁女性，采用分层抽样。第一部分收集人口统计学/疾病特征，包括绝经状态和血管舒缩症状严重程度。有中度至重度血管舒缩症状的女性完成第二部分，包括临床特征、与健康相关的生活质量和医疗保健寻求行为。主要终点包括血管舒缩症状的流行率和严重程度，以及有资格和愿意接受激素治疗的女性比例。结果分别报告了三个在线小组的情况以及汇总情况。所有分析均为描述性的，不针对不同组进行正式假设检验。
完成第一部分的围绝经期和绝经后女性人数分别为艾德曼组 1588 人（55.1% vs 44.9%）；韩康研究所组 1000 人（43.6% vs 56.4%）；乐天洞察组 773 人（61.7% vs 38.3%）。每个地区的血管舒缩症状流行率均为 80%；总体中度至重度血管舒缩症状流行率为 55%；超过 50%的女性未得到治疗。大多数接受治疗的女性使用非处方治疗。围绝经和绝经后女性分别有 11.6%和 7.2%报告使用绝经激素治疗。在有中度至重度血管舒缩症状的围绝经和绝经后女性中，分别有 8.6%和 3.4%愿意接受激素治疗，19.3%和 16.8%有激素治疗禁忌，25.4%和 23.0%谨慎接受激素治疗，10.2%和 8.3%不接受激素治疗。女性的健康相关生活质量受到显著影响，工作生产力和日常活动受到严重损害。
与绝经相关的血管舒缩症状影响了 40-65 岁的 80%女性。相当一部分女性不适合或选择不接受绝经激素治疗，导致对非激素治疗选择存在未满足的需求。
